Virpax Pharmaceuticals Inc (VRPX)

Nov 22, 2024, 8:30 AM EST - 2 months ago

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™

Nov 21, 2024, 4:05 PM EST - 2 months ago

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

Nov 18, 2024, 10:23 AM EST - 2 months ago

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

Nov 15, 2024, 4:09 PM EST - 2 months ago

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 13, 2024, 9:15 AM EST - 2 months ago

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Oct 9, 2024, 12:21 PM EDT - 3 months ago

This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday

FDS BX DQ

Aug 13, 2024, 7:30 AM EDT - 5 months ago

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

Aug 8, 2024, 7:30 AM EDT - 5 months ago

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

Jul 24, 2024, 7:30 AM EDT - 6 months ago

Virpax Regains Compliance with Nasdaq Minimum Bid Price

Jul 10, 2024, 12:12 PM EDT - 6 months ago

Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher

Jul 10, 2024, 11:29 AM EDT - 6 months ago

Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?

Jul 8, 2024, 12:09 PM EDT - 6 months ago

What's Going With Penny Stock Virpax Pharmaceuticals On Monday?

Jul 8, 2024, 7:30 AM EDT - 6 months ago

Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding

May 29, 2024, 7:30 AM EDT - 8 months ago

Virpax® Pharmaceuticals to Present at 2024 BIO International Convention

May 15, 2024, 8:00 AM EDT - 8 months ago

Virpax Announces Pricing of $2.25 Million Public Offering

May 13, 2024, 4:10 PM EDT - 8 months ago

Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

Apr 30, 2024, 7:30 AM EDT - 9 months ago

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™

Mar 26, 2024, 7:30 AM EDT - 10 months ago

Virpax Pharmaceuticals Reports 2023 Year-End Results

Feb 27, 2024, 7:31 AM EST - 11 months ago

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price

Feb 27, 2024, 7:30 AM EST - 11 months ago

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

Feb 7, 2024, 7:30 AM EST - 1 year ago

Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research

Dec 29, 2023, 7:30 AM EST - 1 year ago

Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting

Nov 17, 2023, 7:10 AM EST - 1 year ago

Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing

Nov 17, 2023, 7:00 AM EST - 1 year ago

Virpax Pharmaceuticals Announces Leadership Transition

Nov 15, 2023, 4:15 PM EST - 1 year ago

Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

Oct 31, 2023, 8:58 AM EDT - 1 year ago

Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

Oct 12, 2023, 8:02 AM EDT - 1 year ago

Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research

Sep 27, 2023, 8:58 AM EDT - 1 year ago

Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies

Sep 26, 2023, 8:58 AM EDT - 1 year ago

Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI

Sep 21, 2023, 10:00 AM EDT - 1 year ago

Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses

Sep 18, 2023, 7:58 AM EDT - 1 year ago

Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals

Sep 5, 2023, 9:00 AM EDT - 1 year ago

Virpax Pharmaceuticals Updates on Litigation

SCLX

Aug 28, 2023, 8:58 AM EDT - 1 year ago

Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 9:00 AM EDT - 1 year ago

Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments

Aug 10, 2023, 8:58 AM EDT - 1 year ago

Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method

Jul 24, 2023, 7:00 AM EDT - 1 year ago

Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023

May 12, 2023, 4:08 PM EDT - 1 year ago

Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments

Apr 13, 2023, 5:20 AM EDT - 1 year ago

Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada

Apr 5, 2023, 8:58 AM EDT - 1 year ago

Virpax Reports on Progress of Envelta™

Feb 13, 2023, 8:58 AM EST - 2 years ago

Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)

Jan 31, 2023, 8:58 AM EST - 2 years ago

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

Jan 18, 2023, 9:00 AM EST - 2 years ago

Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™

Jan 10, 2023, 9:00 AM EST - 2 years ago

Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts

Jan 4, 2023, 9:00 AM EST - 2 years ago

Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)

Dec 14, 2022, 9:00 AM EST - 2 years ago

Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)

Nov 9, 2022, 9:00 AM EST - 2 years ago

Virpax Pharmaceuticals Reports 2022 Third Quarter Results

Aug 24, 2022, 9:00 AM EDT - 2 years ago

Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain

Aug 15, 2022, 9:00 AM EDT - 2 years ago

Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments

Jul 5, 2022, 9:00 AM EDT - 2 years ago

Virpax Pursues OTC Medical Device Pathway for AnQlar™

Jun 27, 2022, 9:00 AM EDT - 2 years ago

Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis